Using Xenopus tissue cultures for the study of myasthenia gravis pathogenesis

Hwee Li Yeo1, Jorain Yu Ni Lim1, Yuki Fukami2

  • 1Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.

Developmental Biology
|March 10, 2015
PubMed

Insights

This study introduces a novel Xenopus cell-based assay (CBA) for diagnosing myasthenia gravis (MG). The assay effectively detects pathogenic autoantibodies in MG patient plasma, improving diagnostic capabilities for this neuromuscular junction disorder.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Myasthenia gravis (MG) is a heterogeneous autoimmune neuromuscular junction (NMJ) disorder.
  • Current diagnosis relies on detecting autoantibodies against acetylcholine receptor (AChR) or muscle-specific kinase (MuSK).
  • Existing assays may miss autoantibodies reactive to clustered AChR conformations.

Purpose of the Study:

  • To develop and validate a novel cell-based assay (CBA) for myasthenia gravis (MG) diagnosis using Xenopus primary cultures.
  • To investigate the pathogenic effects of MG patient plasma on acetylcholine receptor (AChR) clusters.
  • To explore the role of actin depolymerizing factor (ADF)/cofilin in MG-induced AChR disassembly.

Main Methods:

  • Utilized Xenopus primary muscle cell cultures and nerve-muscle co-cultures.
  • Examined the effects of human MG plasma samples on AChR clusters.
  • Assessed the spatio-temporal correlation between AChR cluster disassembly and ADF/cofilin levels.

Main Results:

  • MG patient plasma samples induced disassembly of both aneural and nerve-induced AChR clusters in Xenopus cultures.
  • AChR cluster disassembly was correlated with the depletion of actin depolymerizing factor (ADF)/cofilin.
  • The novel Xenopus CBA demonstrated reliability in screening MG plasma pathogenicity.

Conclusions:

  • Xenopus primary cultures provide a reliable platform for a novel cell-based assay (CBA) for myasthenia gravis (MG).
  • This assay can screen the pathogenicity of MG patient plasma, aiding in diagnosis.
  • The findings offer a new model for studying AChR trafficking and degradation mechanisms in MG.